AstraZeneca reported positive Phase 3 PREVAIL trial outcomes for gefurulimab, a self-administered C5 complement inhibitor for anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. The drug met its primary endpoint and all secondary endpoints with statistically significant improvements versus placebo in disease activity scores at 26 weeks. AstraZeneca aims to pursue regulatory filings to expand its presence in treating this rare autoimmune neuromuscular disorder.